Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1277-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1276-2015
Class II · Moderate risk

Captopril Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1275-2015
Class II · Moderate risk

Zonisamide Capsules

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1274-2015
Class II · Moderate risk

Zonisamide Capsules

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1273-2015
Class II · Moderate risk

Famotodine Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1267-2015
Class II · Moderate risk

Famotodine Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1266-2015
Class II · Moderate risk

Famotodine Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1265-2015
Class II · Moderate risk

Azithromycin Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1264-2015
Class II · Moderate risk

Azithromycin Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1263-2015
Class II · Moderate risk

Zolpidem Tartrate Tablets

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1262-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1261-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1260-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1259-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1258-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1257-2015
Class II · Moderate risk

Zonisamide Capsules

CGMP Deviations: Firm did not adequately investigate customer complaints.

Terminated cGMP deviation Wockhardt Usa Inc. D-1254-2015